ASH 2022 Abstracts

View All

Bispecific Antibodies in DLBCL, Opportunities and Challenges
ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges

The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL.  Recently, off-the-shelf bispecific antibodies have grow...

Find More

Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market at the ASH 2022
ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market

American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their result...

Find More

ASH Annual Meeting, Major Abstracts, Breakthroughs, Updates, and News
ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experiments and their upshots are always brought to us through various platforms, the American S...

Find More